Stocky turns companies like Pulse Biosciences, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Pulse Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Clinical trial progress shows the company's atrial fibrillation treatment is advancing toward approval and eventual sales.
Annual meeting results show shareholders support the company's leadership and financial oversight.
Warrant redemption at $0.01 per share simplifies the company's share structure and affects investor options.
Company spent more on research and development than it earned, which is typical for early-stage medical device firms.
Company can raise cash by selling shares, and co-founders indicate they may buy shares at market price.
Strong clinical trial results presented at Heart Rhythm conference strengthen the path toward regulatory approval.
Stocky reads Pulse Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Pulse Biosciences, Inc.'s most recent tracked filing was a 8-K on 29 Jul 2026: Surpasses enrollment midpoint in NANOPULSE-AF cardiac study.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.